Côd QR

PD-L1 has a heterogeneous and dynamic expression in gastric cancer with implications for immunoPET

IntroductionThis study aimed to investigate the dynamics of programmed death-ligand 1 (PD-L1) expression, spatial heterogeneity, and binding affinity of FDA-approved anti-PD-L1 antibodies (avelumab and atezolizumab) in gastric cancer. Additionally, we determined how PD-L1 glycosylation impacts antib...

Disgrifiad llawn

Wedi'i Gadw mewn:
Prif Awduron: Dina Ibrahim, Cristina Simó, Emma L. Brown, Shayla Shmuel, Sandeep Surendra Panikar, Alex Benton, Rachel DeWeerd, Farrokh Dehdashti, Haeseong Park, Patrícia M. R. Pereira
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Frontiers Media S.A. 2024-06-01
Cyfres:Frontiers in Immunology
Pynciau:
PD-L1
N-glycosylation
gastric tumors
immunoPET
avelumab
atezolizumab
Mynediad Ar-lein:https://www.frontiersin.org/articles/10.3389/fimmu.2024.1405485/full
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg